<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-title-group><journal-title>Journal of Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1479-5876-7-56</article-id><article-id pub-id-type="pmid">19583834</article-id><article-id pub-id-type="doi">10.1186/1479-5876-7-56</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Higher percentage of CD133<sup>+ </sup>cells is associated with poor prognosis in colon carcinoma patients with stage IIIB</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Li</surname><given-names>Chun-Yan</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I5">5</xref><email>lichyanun@hotmail.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Li</surname><given-names>Bao-Xiu</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I6">6</xref><email>libaoxiu@csco.org.cn</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Liang</surname><given-names>Yi</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>liangyi_best@163.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Peng</surname><given-names>Rui-Qing</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>gz13724083175@126.com</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Ding</surname><given-names>Ya</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>dingya@mail.sysu.edu.cn</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Xu</surname><given-names>Da-Zhi</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>dazhi@163.com</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Zhang</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>xingzhang@hotmail.com</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Pan</surname><given-names>Zhi-Zhong</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>panzhzh@mail.sysu.edu.cn</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Wan</surname><given-names>De-Sen</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>wds-fk@yahoo.com.cn</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Zeng</surname><given-names>Yi-Xin</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I4">4</xref><email>zengyix@mail.sysu.edu.cn</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Zhu</surname><given-names>Xiao-Feng</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>zuxfeng@mail.sysu.edu.cn</email></contrib><contrib contrib-type="author" corresp="yes" id="A12"><name><surname>Zhang</surname><given-names>Xiao-Shi</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>zxs617@hotmail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, PR China</aff><aff id="I2"><label>2</label>Biotherapy Center, Cancer Center, Sun Yat-sen University, Guangzhou, PR China</aff><aff id="I3"><label>3</label>Department of Abdominal Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, PR China</aff><aff id="I4"><label>4</label>Department of Experimental Research, Cancer Center, Sun Yat-sen University, Guangzhou, PR China</aff><aff id="I5"><label>5</label>Biotherapy Center, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China </aff><aff id="I6"><label>6</label>GuangZhou First Municipal People's Hospital, Guangzhou, China</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>7</day><month>7</month><year>2009</year></pub-date><volume>7</volume><fpage>56</fpage><lpage>56</lpage><history><date date-type="received"><day>29</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>7</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2009 Li et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Li et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.translational-medicine.com/content/7/1/56"/><abstract><sec><title>Background</title><p>Cancer stem cell model suggested that tumor progression is driven by the overpopulation of cancer stem cells and eradicating or inhibiting the symmetric division of cancer stem cells would become the most important therapeutic strategy. However, clinical evidence for this hypothesis is still scarce. To evaluate the overpopulation hypothesis of cancer stem cells the association of percentage of CD133<sup>+ </sup>tumor cells with clinicopathological parameters in colon cancer was investigated since CD133 is a putative cancer stem cell marker shared by multiple solid tumors.</p></sec><sec><title>Patients and methods</title><p>Tumor tissues matched with adjacent normal tissues were collected from 104 stage IIIB colon cancer patients who were subject to radical resection between January, 1999 to July, 2003 in this center. The CD133 expression was examined with immunohistochemical staining. The correlation of the percentage of CD133<sup>+ </sup>cell with clinicopathological parameters and patients' 5-year survival was analyzed.</p></sec><sec><title>Results</title><p>The CD133<sup>+ </sup>cells were infrequent and heterogeneous distribution in the cancer tissue. Staining of CD133 was localized not only on the glandular-luminal surface of cancer cells but also on the invasive budding and the poorly differentiated tumors with ductal structures. Both univariate and multivariate survival analysis revealed that the percentage of CD133<sup>+ </sup>cancer cells and the invasive depth of tumor were independently prognostic. The patients with a lower percentage of CD133<sup>+ </sup>cancer cells (less than 5%) were strongly associated with a higher 5-year survival rate than those with a higher percentage of CD133<sup>+ </sup>cancer cells (greater than or equal to 55%). Additionally, no correlation was obtained between the percentage of CD133<sup>+ </sup>cancer cells and the other clinicopathological parameters including gender, age, site of primary mass, pathologic types, grades, and invasive depth.</p></sec><sec><title>Conclusion</title><p>The fact that a higher percentage CD133<sup>+ </sup>cells were strongly associated with a poorer prognosis in patients with locally advanced colon cancer implicated that CD133<sup>+ </sup>cancer cells contribute to the tumor progression, and the overpopulation hypothesis of cancer stem cell seems reasonable.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Colorectal cancer is one of the most common causes of cancer death worldwide. Although the median overall survival of patients with metastatic colorectal cancer has increased from 12 months to approximately 24 months over the past decade as a result of an improvement in systemic therapies including new chemotherapeutic agents such as CPT-11 and oxaliplatin and monoclonal antibodies against EGFR (cetuximab and panitumumab) and VEGF (bevacizumab), the 5-year survival is still pessimistic [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. Therefore, one of the main challenges in colorectal carcinoma remains to develop new strategies beyond chemotherapy to inhibit the disease progression.</p><p>A growing body of evidence supports the notion that only a small subset of cells within a solid tumor have 'stem-like' characteristics. These tumor-initiating cells, or cancer stem cells, distinct from non-malignant stem cells, show low proliferative rates, high self-renewal capacity, propensity to differentiate into active proliferating tumor cells, and resistance to chemotherapy or radiation [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Until now, cancer stem cells have been identified in a great deal of solid tumors [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Multiple cancer stem cell-associated markers have been identified, among which CD133 has received considerable attention. CD133 or prominin-1 gene is located on chromosome 4p15.32 and encodes a cell surface glycoprotein compromising five transmembrane domain and two large glycosylated extracellular loops [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. The transcription of CD133 can be initiated at five tissue specific promoters, yielding eight alternatively spliced transcripts [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Epigenetic mechanism is involved in the regulation of CD133 expression [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. Although the function of CD133 is unknown, preliminary evidence proposed that expression of CD133 is associated with the activation of stemness-related signal pathway, resistance to apoptosis and bioenergetic stress [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. Initially identified in hematopoietic stem cells, CD133 is now shared as cancer stem cell marker across multiple kinds of solid tumors, such as those in the brain, breast, lung, liver, colon, prostate, pancreatic carcinomas, medulloblastoma, and melanoma [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B29">29</xref>].</p><p>As for colorectal cancer, initially, Ricci-vitiani and O'Brien observed that colon cancer stem cells are located in the CD133<sup>+ </sup>subpopulation, which accounts for approximately 2.5% of the tumor cells [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Subsequently, Dalerba and Haraguchi reported that markers for colon cancer stem cells are EpCAM <sup>hi</sup>/CD44<sup>+</sup>/CD166<sup>+ </sup>[<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. In addition, Barker proposed that Lgr5 is another marker [<xref ref-type="bibr" rid="B34">34</xref>]. CD133<sup>+ </sup>colon cancer cells include EpCAM <sup>hi</sup>/CD44<sup>+ </sup>cells, whereas the relationship between CD133<sup>+ </sup>subset and Lgr5<sup>+ </sup>subset is unclear. Therefore, which protein would be an ideal marker for colorectal cancer stem cells remains an open question.</p><p>Based on the mathematic model, the hypothesis that development of colorectal carcinoma is driven by overpopulation of stem cells has been suggested. It is believed that the abundance of cancer stem cells is derived from their symmetric division, whereas their normal partners are subject to asymmetric division, therefore, eradicating or inhibiting the symmetric division of cancer stem cells would become the most important strategy for cancer treatment [<xref ref-type="bibr" rid="B35">35</xref>-<xref ref-type="bibr" rid="B39">39</xref>]. If the percentage of cancer stem cells is associated with the prognosis of cancer patients, the overpopulation hypothesis would be substantially supported. By now, the relationship between the percentage of CD133 and prognosis of colorectal carcinomas was controversial. Horst reported that CD133 expression is an independently prognostic marker whereas this kind of correlation was not confirmed by Kojima[<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref>]. Accordingly, more evidence was need to elucidate the relationship between the percentage of CD133<sup>+ </sup>tumor cells and the prognosis of colorectal cancer patients. This study showed that the percentage of CD133<sup>+ </sup>tumor cells was associated with the prognosis among patients with locally advanced colon cancers, implicating that CD133<sup>+ </sup>cells are involved in the progression of colon cancer.</p></sec><sec sec-type="methods"><title>Patients and methods</title><sec><title>Patients and Follow-up</title><p>104 cases of pathologically confirmed specimens were obtained from colon carcinoma patients with TNM stage IIIB (the depth of primary invasive spread defined as T3 and T4 with one to three regional node involvement but no distant metastasis) who were subject to radical resection between January, 1999 and July, 2003 in the Cancer Center of Sun Yat-Sen University, Guangzhou, China. None of the patients had undergone either chemotherapy or radiotherapy before the collection of the samples. All of them were subject to 5-Fu based postoperatively adjuvant chemotherapy for six months. Patients were observed on an every-three-month basis during the first year, once every 6 months in the second year, and by telephone or mail communication once every year thereafter for a total of 5 years. If recurrence or metastasis occurred, 5-Fu based chemotherapy was given according to the NCCN guideline. Overall survival was defined as the time from operation to death or was censored at the last known alive data. Histopaothologic characteristics were confirmed by blinded review of the original pathology slides. The TNM classification was used for pathologic staging, and the World Health Organization classification was used for pathologic grading.</p></sec><sec><title>Immunohistochemical assay</title><p>The expression of CD133 in primary tumors matched with adjacent noncancerous tissue was examined with immunohistochemical assay. Briefly, formalin-fixed, paraffin-embedded archived tissues were subject to 4-&#x003bc;m section. Then, sections were subject to dewax, rehydration, blocking with hydrogen peroxide, and antigen retrieval with microwave in a 10 mM citrate buffer (pH 6.0) for 10 min and cooled to room temperature. After being blocked with 1% goat serum albumin sections were incubated with the mouse monoclonal antibodies against human CD133 at a dilution of 1:150 (Abcam, Cambridge, UK) overnight at 4&#x000b0;C, followed with horseradish peroxidase-labeled secondary antibodies for 30 minutes at room temperature. The sections were developed with diaminobenzidine tetrahydrochloride (DAB) and counterstained with hematoxylin. Immunohistochemical assay was performed within 7 days of section preparation. To prevent antigen degradation sections were stored at 4&#x000b0;C before immunohistochemical analysis. Tissue derived from glioma was used as positive control and negative controls were made with primary antibody replaced by PBS.</p><p>Referring to Maeda's method, slides were examined under low power (&#x000d7;40 ~ &#x000d7;200) microscope to identify the regions containing the highest percentage of CD133<sup>+ </sup>cells (hot spot) in the cancer nest [<xref ref-type="bibr" rid="B42">42</xref>]. Ten fields of hot spot inside the tumor tissue were selected, and expression of CD133 was evaluated in 1000 tumor cells (100 cells per field) with high power (&#x000d7;400) microscopy. Specimens were defined as positive for CD133 expression if there were tumor cells distinctly stained by the anti-CD133 antibodies. The percentage of CD133<sup>+ </sup>cells was classified into two levels: &#x0003c; 5% CD133-positive cells and &#x02265; 5% CD133-positive cells[<xref ref-type="bibr" rid="B42">42</xref>].</p></sec><sec><title>Statistical analysis</title><p>The following factors were assessed with both univariate and multivariate analyses for their influence on overall survival: gender, age (&#x0003c;60 years old vs &#x02265; 60 years old), sites of primary mass (left hemicolon vs right hemicolon), the T stages (the depth of primary invasive spread, T3 vs T4), pathological classifications (papillary carcinoma and tubular adenocarcinoma vs mucoid adenocarcinoma and signet ring cell carcinoma), tumor grades (the degree of cellular differentiation, well differentiated, G1 vs moderate differentiated, G2 vs poorly differentiated, G3), and the percentage of the CD133<sup>+ </sup>cells (&#x0003c;5% positive vs &#x02265;5% positive). The nonparametric correlation Kendall's tau-b test was used to assess associations between categorical variables. Kaplan-Meier curves were used to estimate the distributions of clinicopathological characteristics to survival and compared with the log-rank test. The Cox regression model was used to correlate assigned variables with overall survival. All statistical analyses were carried out using SPSS 15.0 software (SPSS Inc, Chicago, IL, USA). Statistical significance was assumed for a two-tailed <italic>P </italic>&#x0003c; 0.05.</p></sec></sec><sec><title>Results</title><sec><title>Expression of CD133 in tumor tissue</title><p>CD133 brownish signals were observed on the cell membrane, especially on its luminal and basal surface. In general, the cases with intensive staining of CD133 had higher percentage of CD133<sup>+</sup> tumor cells. Several nests with intensive CD133 staining, so-called "hotspot" could always be seen within the field of cancer nests microscopically (Fig <xref ref-type="fig" rid="F1">1A</xref> to <xref ref-type="fig" rid="F1">1D</xref>). The cancer cells within an adenocarcinoma nest could actively proliferate and form a group of cells, which invaded into the surrounding tissue, so-called "budding", and showed negative or weak staining against CD133 (Fig <xref ref-type="fig" rid="F1">1E</xref>). Besides staining on the well differentiated tumors CD133 staining was documented on the poorly differentiated tumors with ductal structures rather than those without ductal structures (Fig <xref ref-type="fig" rid="F1">1F</xref>). The paratumorous normal intestinal epithelium could be found in 72 out of 104 specimens used for this study. The CD133 expression of normal intestinal epithelium was only found in 7 out of the 72 specimens.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>The expression of CD133 in colon cancer patients with stage IIIB (10 &#x000d7; 20~10 &#x000d7; 100)</bold>. The expression of CD133 was examined with immunohistochemical assay. (A): &#x0003c;5% CD133<sup>+ </sup>cells in the cancer nest; (B): &#x02265;5% CD133<sup>+ </sup>cells in the cancer nest; (C) and (D): the staining of CD133 on the luminal surface and the basal surface of cancer cells; (E): the staining of CD133 on budding cancer nest; (F): the staining of CD133 on poor-differentiated cancer nests with ductal structures.</p></caption><graphic xlink:href="1479-5876-7-56-1"/></fig><p>Referring to Maeda's method the percentage of CD133<sup>+ </sup>cells was classified into two levels: &#x0003c; 5% CD133<sup>+ </sup>cells and &#x02265; 5% CD133<sup>+ </sup>cells [<xref ref-type="bibr" rid="B39">39</xref>]. In this group of patients, 62 cases of 104 (59.6%) specimens contained less than 5% CD133-positive tumor cells and 42 cases (40.4%) contained more than 5% CD133-positive tumor cells, among which the percentage of CD133<sup>+ </sup>cells varying from 5% to 25% existed in 23 cases, from 26% to 50% in 12 cases, and more than 50% in 7 cases.</p></sec><sec><title>Relationship between the percentage of CD133<sup>+ </sup>cells and clinicopathological characteristics</title><p>No correlation was observed between the expression of CD133 and clinicopathological parameters such as age, gender, sites of primary mass, pathological classifications, invasive depth, and tumor grades. Otherwise, the analysis revealed that mucoid adenocarcinomas and signet ring cell carcinomas had the potential with poorer differentiation (r = 0.459, <italic>P </italic>&#x0003c; 0.001) and higher frequency occurred in the right hemicolon (r = 0.215, <italic>P </italic>= 0.022) (Tab <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Correlations of CD133 expression with clinicopathological parameters in the Stage IIIB colon carcinomas</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th/><th align="left">gender</th><th align="left">age</th><th align="left">Invasive depth</th><th align="left">Sites of primary mass</th><th align="left">Grades</th><th align="left">Pathological classifications</th><th align="left">The percentage of CD133<sup>+ </sup>cells</th></tr></thead><tbody><tr><td align="left">gender</td><td align="left">P</td><td align="left">.</td><td align="left">.242</td><td align="left">.541</td><td align="left">.792</td><td align="left">.129</td><td align="left">.129</td><td align="left">.785</td></tr><tr><td align="left">age</td><td align="left">P</td><td align="left">.242</td><td align="left">.</td><td align="left">.312</td><td align="left">.075</td><td align="left">.455</td><td align="left">.869</td><td align="left">.249</td></tr><tr><td align="left">Invasive depth</td><td align="left">P</td><td align="left">.541</td><td align="left">.312</td><td align="left">.</td><td align="left">.895</td><td align="left">.272</td><td align="left">.426</td><td align="left">.499</td></tr><tr><td align="left">Sites of primary mass</td><td align="left">P</td><td align="left">.792</td><td align="left">.075</td><td align="left">.895</td><td align="left">.</td><td align="left">.936</td><td align="left">.022*</td><td align="left">.786</td></tr><tr><td align="left">Grades</td><td align="left">P</td><td align="left">.129</td><td align="left">.455</td><td align="left">.272</td><td align="left">.936</td><td align="left">.</td><td align="left">.000**</td><td align="left">.536</td></tr><tr><td align="left">Pathological classifications</td><td align="left">P</td><td align="left">.129</td><td align="left">.869</td><td align="left">.426</td><td align="left">.022*</td><td align="left">.000**</td><td align="left">.</td><td align="left">.333</td></tr><tr><td align="left">The percentage of CD133<sup>+ </sup>cells</td><td align="left">P</td><td align="left">.785</td><td align="left">.249</td><td align="left">.499</td><td align="left">.786</td><td align="left">.536</td><td align="left">.333</td><td align="left">.</td></tr></tbody></table><table-wrap-foot><p>*: <italic>P </italic>&#x0003c; 0.05; **: <italic>P </italic>&#x0003c; 0.001</p></table-wrap-foot></table-wrap></sec><sec><title>Relationship between survival and clinicopathological characteristcs assessed with univariate survival analysis</title><p>By the end of the 5-year follow-up, 67 cases were still alive. So, the 5-year survival rate was 64.4%. Kaplan-Meier analysis revealed that the percentage of CD133<sup>+ </sup>cells in cancer nests and the invasive depth of primary mass were prognostic. The 5-year survival rate among patients with a higher percentage of CD133<sup>+ </sup>cells (&#x02265;5%) in the cancer nests was 45.2%, whereas those with a lower percentage of CD133<sup>+ </sup>cells (&#x0003c;5%) was 77.4% (<italic>P </italic>= 0.001). In addition, the 5-year survival rate among patients with T3 tumors (tumors which invade through the muscular propria into the subserosa, or into nonperitonealizd pericolic tissue) was 69.6%, whereas the 5-year survival rate among patients with T4 tumors (tumors which perforate the visceral peritoneum or directly invade other organs or structure) was 25.0% (<italic>P </italic>= 0.001)(Tab <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Assessment of overall survival for stage IIIB colon carcinoma patients by clinicopathological parameters with univariate and multivariate analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Clinicopaothological characteristics</th><th align="center">N<break/>(n = 104)</th><th align="center">5-year survival</th><th align="center">Kaplan-Meier analysis<break/><italic>P </italic>value</th><th align="center">Cox regression model analysis<break/><italic>P </italic>value</th></tr></thead><tbody><tr><td/><td/><td align="center">64.4%</td><td/><td/></tr><tr><td align="left">Gender</td><td/><td/><td align="center">0.461</td><td align="center">0.479</td></tr><tr><td align="left">&#x02003;male</td><td align="center">65</td><td align="center">61.5%</td><td/><td/></tr><tr><td align="left">&#x02003;female</td><td align="center">39</td><td align="center">69.2%</td><td/><td/></tr><tr><td/><td/><td align="center">64.4%</td><td/><td/></tr><tr><td align="left">Age</td><td/><td/><td align="center">0.148</td><td align="center">0.211</td></tr><tr><td align="left">&#x02003;&#x02265; 60 year old</td><td align="center">57</td><td align="center">57.9%</td><td/><td/></tr><tr><td align="left">&#x02003;&#x0003c;60 year old</td><td align="center">47</td><td align="center">72.3%</td><td/><td/></tr><tr><td/><td/><td align="center">64.4%</td><td/><td/></tr><tr><td align="left">Sites of primary mass</td><td/><td/><td align="center">0.291</td><td align="center">0.381</td></tr><tr><td align="left">&#x02003;Left hemicolon</td><td align="center">60</td><td align="center">68.3%</td><td/><td/></tr><tr><td align="left">&#x02003;Right hemicolon</td><td align="center">44</td><td align="center">59.1%</td><td/><td/></tr><tr><td/><td/><td align="center">64.4%</td><td/><td/></tr><tr><td align="left">Pathological classifications</td><td/><td/><td align="center">0.423</td><td align="center">0.139</td></tr><tr><td align="left">papillary + tubular</td><td align="center">82</td><td align="center">65.9%</td><td/><td/></tr><tr><td align="left">mucoid + signet ring</td><td align="center">22</td><td align="center">59.1%</td><td/><td/></tr><tr><td/><td/><td align="center">64.4%</td><td/><td/></tr><tr><td align="left">Grades</td><td/><td/><td align="center">0.154</td><td align="center">0.114</td></tr><tr><td align="left">&#x02003;&#x02003;G1</td><td align="center">5</td><td align="center">60%</td><td/><td/></tr><tr><td align="left">&#x02003;&#x02003;G2</td><td align="center">80</td><td align="center">68.8%</td><td/><td/></tr><tr><td align="left">&#x02003;&#x02003;G3</td><td align="center">19</td><td align="center">47.4%</td><td/><td/></tr><tr><td/><td/><td align="center">64. 4%</td><td/><td/></tr><tr><td align="left">Invasive depth</td><td/><td/><td align="center">0.001</td><td align="center">0.002</td></tr><tr><td align="left">&#x02003;T3</td><td align="center">92</td><td align="center">69.6%</td><td/><td/></tr><tr><td align="left">&#x02003;T4</td><td align="center">12</td><td align="center">25.0%</td><td/><td/></tr><tr><td/><td/><td align="center">64.4%</td><td/><td/></tr><tr><td align="left">The percentage of CD133<sup>+ </sup>cells</td><td/><td/><td align="center">0.001</td><td align="center">0.004</td></tr><tr><td align="left">&#x02003;&#x02265;5% CD133 positive</td><td align="center">42</td><td align="center">45.2%</td><td/><td/></tr><tr><td align="left">&#x02003;&#x0003c;5%CD133 positive</td><td align="center">62</td><td align="center">77.4%</td><td/><td/></tr></tbody></table></table-wrap></sec><sec><title>Relationship between survival and clinicopathological characteristics assessed with multivariate survival analysis</title><p>The Cox regression model revealed that the patients with a lower percentage CD133<sup>+ </sup>cells (&#x0003c;5%) in the cancer nests were significantly associated with a higher 5-year survival rate with -0.987 in partial regression coefficient and 0.373 (95% CI 0.190 ~ 0.732) in relative risk (<italic>P </italic>= 0.004). Additionally, a higher T stage (invasive depth) was significantly associated with a lower survival rate with 1.209 in partial regression coefficient and 3.351 (95% CI 1.558 ~7.208) in relative risk (<italic>P </italic>= 0.002). Therefore, the percentage of CD133<sup>+ </sup>cells in cancer nests and T stage were independently prognostic factors. No relationship was observed between the survival and the other clinicopathological parameters such as age, gender, site of primary mass, pathological classifications, and grades (Tab <xref ref-type="table" rid="T2">2</xref>, Fig <xref ref-type="fig" rid="F2">2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>The association of overall survival with the percentage of CD133+ cells in colon carcinoma patients with Stage IIIB</bold>. The patients with a lower percentage of CD133<sup>+ </sup>cells (&#x0003c;5%) in the cancer nests were strongly associated with longer 5-year survival than those with a higher percentage of CD133<sup>+ </sup>cells (&#x02265;5%).</p></caption><graphic xlink:href="1479-5876-7-56-2"/></fig></sec></sec><sec><title>Discussion</title><p>This study showed that a higher percentage of CD133<sup>+ </sup>cells in cancer nests was strongly associated with the lower 5-year survival rate in colon cancer patients with stage IIIB, a locally advanced disease among which most of patients would die from metastasis in spite of adjuvant chemotherapy, implying that the overpopulation hypothesis of cancer stem cell seems reasonable as CD133 is a putative marker of colon cancer stem cells.</p><p>The evidence concerning the correlation of the percentage of CD133<sup>+ </sup>tumor cells with the prognosis of patients was scarce as a few of observations were reported [<xref ref-type="bibr" rid="B43">43</xref>-<xref ref-type="bibr" rid="B46">46</xref>]. Recently the relationship between CD133 expression and prognosis in colorectal carcinomas was examined. Horst reported that CD133 expression is an independently prognostic marker whereas this kind of correlation was not observed by Kojima. [<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref>] The discrepancy might derived from inadequate patient quantity and the mixed tumor stage. For example, in Kojima's study, a total of 189 patients consisted of 106 cases of colon cancers and 83 cases of rectal cancers with TNM stages varying from I to VI, that is, one group of patients with a definite stage contained only 20 or 30 cases of colon or rectal cancer patients, respectively[<xref ref-type="bibr" rid="B41">41</xref>]. Similar situation existed in Horst's study [<xref ref-type="bibr" rid="B40">40</xref>]. To narrow the heterogeneity of patients and make the results more reproducible this study included 104 cases of colon carcinoma patients with stage IIIB. The results showed that CD133<sup>+ </sup>cancer cells contributed to the progression of colon cancer, arguing the Hosrt's observation.</p><p>The discrepancy concerning the pattern and the frequency of CD133 expression in colon cancer also existed between the studies mentioned above and this study. Horst and Kojima reported that CD133 antigen, stained with antibodies from Miltenyi Biotech, Sata Cruz Biotechnology, or Cell signaling, was localized exclusively on the glandular-luminal surface of colorectal cancer. Staining of the CD133 was observed neither on the budding cancer nest nor on poorly differentiated cancer cells [<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref>]. However, in this study, being stained with antibodies from Abcam CD133 expression existed not only on the apical membrane but also on basal surface of tumor cells, both on the budding cancer nest (the invasive front) and on the poorly differentiated cancer cells, although the intensity of staining was weaker. This pattern of CD133 expression might be more likely consistent with the hypothesis that CD133<sup>+ </sup>cancer cells would reveal a more aggressive phenotype. Since the intensity of CD133 is cell cycle-dependent, among which the least CD133 immunoreactive cells are in the G0/G1 portion, and the increased CD133<sup>+ </sup>cells is correlated with increased DNA content, and cancer cells is relatively arrested in the invasive front, so, attenuated expression of CD133 occurred in the invasive front (budding)[<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B48">48</xref>]. As for the frequency of CD133<sup>+ </sup>cells in colorectal cancers the discrepancy also existed. In Kojima's study CD133 expression was detected in only 29 of the 189 tumors (15.3%). Of these, 21 tumors (11.1%) showed CD133 over-expression among which CD133 positive area occupied more than 10% of the entire tumor tissue[<xref ref-type="bibr" rid="B41">41</xref>]. Otherwise, in Horst's study tumors with more than 50% of CD133<sup>+ </sup>tumor cells exist in 20 out of 79 colorectal cancers (25.3%) [<xref ref-type="bibr" rid="B40">40</xref>]. In this study, the percentage of CD133+ cells varying from 5% to 25% existed in 23 cases (22.1%), from 26% to 50% in 12 cases (11.5%), and more than 50% in 7 cases (6.7%). Therefore, it is reasonable to infer that the heterogeneous patterns and frequencies of CD133 expression in colon cancer derived from the specificity of antibody clones used. In the future, more attention should be paid to the specificity of CD133-targeting antibodies, the standardization of the CD133 positive cells classification system, and homogeneity of tissues.</p><p>Recently the representative of CD133 as marker of colon cancer stem cells was questioned. On the one hand, CD133<sup>+ </sup>colon cancer cells revealed 'stem-like' characteristics, and stem cells marked by CD133 was susceptible to transformation into tumors[<xref ref-type="bibr" rid="B49">49</xref>]. On the other hand, CD133 expression was detected not only on cancer cells, but also on the luminal layer of epithelium of digestion duct, on the mature epithelium of the pancreatic duct, on the proximal tubules of the kidney, and on the lactiferous ducts of the mammary gland [<xref ref-type="bibr" rid="B50">50</xref>-<xref ref-type="bibr" rid="B52">52</xref>]. Furthermore, both CD133<sup>+ </sup>and CD133<sup>- </sup>metastatic colon cancer cells initiated tumors[<xref ref-type="bibr" rid="B50">50</xref>]. Additionally, CD44<sup>+ </sup>cancer cells rather than CD133<sup>+ </sup>cells have an increased tumorigenicity[<xref ref-type="bibr" rid="B53">53</xref>]. Those data pointed that CD133 should not be a unique marker for colon cancer stem cells. It is less likely that a known marker for colon cancer stem cells, such as CD44, CD166, EpCAM, and Lgr5, has the potential just like Pten-related pathway in leukemia, which could distinguish hematopoietic stem cells from leukemia-initiating cells [<xref ref-type="bibr" rid="B54">54</xref>-<xref ref-type="bibr" rid="B57">57</xref>]. Collectively, a combination of cell surface markers is need for the definition of colon cancer stem cells [<xref ref-type="bibr" rid="B58">58</xref>-<xref ref-type="bibr" rid="B60">60</xref>]. This study implied that, given that CD133 may not represent all the entire cancer stem cells, it is still a useful biomarker as CD133<sup>+ </sup>cells is more aggressive than CD133<sup>- </sup>partners in colon cancer.</p></sec><sec><title>Conclusion</title><p>The fact that a higher percentage of CD133<sup>+ </sup>cells is strongly associated with a poorer prognosis implicates that CD133<sup>+ </sup>cells contribute to the progression of colon cancer, and the overpopulation hypothesis of cancer stem cell seems reasonable.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>XDZ, PRQ, DY, ZX, PZZ, and WDS carried out the cases collection, LCY and LY carried out the immunohistochemical staining work, LBX and ZXF analyzed results. ZXS and ZYX conceived of the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript</p></sec></body><back><sec><title>Acknowledgements</title><p>This study was supported by the National Nature Science Foundation (30872931) and the Nature Science Foundation of Guangdong Province, China (05001693). The authors thanked Prof. Yong-Shen Zong for his commit on the immunohistochemical analysis.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Meyerhardt</surname><given-names>JA</given-names></name><name><surname>Mayer</surname><given-names>RJ</given-names></name><article-title>Systemic therapy for colorectal cancer</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><issue>5</issue><fpage>476</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1056/NEJMra040958</pub-id><pub-id pub-id-type="pmid">15689586</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name><article-title>Cancer statistics, 2008</article-title><source>CA Cancer J Clin</source><year>2008</year><volume>58</volume><issue>2</issue><fpage>71</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.3322/CA.2007.0010</pub-id><pub-id pub-id-type="pmid">18287387</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Omura</surname><given-names>K</given-names></name><article-title>Advances in chemotherapy against advanced or metastatic colorectal cancer</article-title><source>Digestion</source><year>2008</year><volume>77</volume><issue>Suppl 1</issue><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1159/000111483</pub-id><pub-id pub-id-type="pmid">18204257</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Hecht</surname><given-names>JR</given-names></name><article-title>Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice</article-title><source>Am J Health Syst Pharm</source><year>2008</year><volume>65</volume><issue>11 Suppl 4</issue><fpage>S15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.2146/ajhp080102</pub-id><pub-id pub-id-type="pmid">18499885</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Al-Hajj</surname><given-names>M</given-names></name><name><surname>Wicha</surname><given-names>MS</given-names></name><name><surname>Benito-Hernandez</surname><given-names>A</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name><article-title>Prospective identification of tumorigenic breast cancer cells</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><issue>7</issue><fpage>3983</fpage><lpage>3988</lpage><pub-id pub-id-type="pmid">12629218</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0530291100</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name><name><surname>Clarke</surname><given-names>ID</given-names></name><name><surname>Squire</surname><given-names>JA</given-names></name><name><surname>Bayani</surname><given-names>J</given-names></name><name><surname>Hide</surname><given-names>T</given-names></name><name><surname>Henkelman</surname><given-names>RM</given-names></name><name><surname>Cusimano</surname><given-names>MD</given-names></name><name><surname>Dirks</surname><given-names>PB</given-names></name><article-title>Identification of human brain tumour initiating cells</article-title><source>Nature</source><year>2004</year><volume>432</volume><issue>7015</issue><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/nature03128</pub-id><pub-id pub-id-type="pmid">15549107</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Boman</surname><given-names>BM</given-names></name><name><surname>Wicha</surname><given-names>MS</given-names></name><article-title>Cancer stem cells: a step toward the cure</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>17</issue><fpage>2795</fpage><lpage>2799</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.17.7436</pub-id><pub-id pub-id-type="pmid">18539956</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>LP</given-names></name><name><surname>Chen</surname><given-names>LZ</given-names></name><name><surname>Zeng</surname><given-names>YX</given-names></name><name><surname>Lu</surname><given-names>SH</given-names></name><article-title>Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>8</issue><fpage>3716</fpage><lpage>3724</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4343</pub-id><pub-id pub-id-type="pmid">17440084</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Shmelkov</surname><given-names>SV</given-names></name><name><surname>St Clair</surname><given-names>R</given-names></name><name><surname>Lyden</surname><given-names>D</given-names></name><name><surname>Rafii</surname><given-names>S</given-names></name><article-title>AC133/CD133/Prominin-1</article-title><source>Int J Biochem Cell Biol</source><year>2005</year><volume>37</volume><issue>4</issue><fpage>715</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2004.08.010</pub-id><pub-id pub-id-type="pmid">15694831</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Miraglia</surname><given-names>S</given-names></name><name><surname>Godfrey</surname><given-names>W</given-names></name><name><surname>Yin</surname><given-names>AH</given-names></name><name><surname>Atkins</surname><given-names>K</given-names></name><name><surname>Warnke</surname><given-names>R</given-names></name><name><surname>Holden</surname><given-names>JT</given-names></name><name><surname>Bray</surname><given-names>RA</given-names></name><name><surname>Waller</surname><given-names>EK</given-names></name><name><surname>Buck</surname><given-names>DW</given-names></name><article-title>A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning</article-title><source>Blood</source><year>1997</year><volume>90</volume><issue>12</issue><fpage>5013</fpage><lpage>5021</lpage><pub-id pub-id-type="pmid">9389721</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Flint</surname><given-names>A</given-names></name><name><surname>Dvorin</surname><given-names>EL</given-names></name><name><surname>Bischoff</surname><given-names>J</given-names></name><article-title>AC133-2, a novel isoform of human AC133 stem cell antigen</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><issue>23</issue><fpage>20711</fpage><lpage>20716</lpage><pub-id pub-id-type="doi">10.1074/jbc.M202349200</pub-id><pub-id pub-id-type="pmid">12042327</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Bauer</surname><given-names>N</given-names></name><name><surname>Fonseca</surname><given-names>AV</given-names></name><name><surname>Florek</surname><given-names>M</given-names></name><name><surname>Freund</surname><given-names>D</given-names></name><name><surname>J&#x000e1;szai</surname><given-names>J</given-names></name><name><surname>Bornh&#x000e4;user</surname><given-names>M</given-names></name><name><surname>Fargeas</surname><given-names>CA</given-names></name><name><surname>Corbeil</surname><given-names>D</given-names></name><article-title>New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133)</article-title><source>Cells Tissues Organs</source><year>2008</year><volume>188</volume><issue>1&#x02013;2</issue><fpage>127</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1159/000112847</pub-id><pub-id pub-id-type="pmid">18160824</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>J&#x000e1;szai</surname><given-names>J</given-names></name><name><surname>Fargeas</surname><given-names>CA</given-names></name><name><surname>Florek</surname><given-names>M</given-names></name><name><surname>Huttner</surname><given-names>WB</given-names></name><name><surname>Corbeil</surname><given-names>D</given-names></name><article-title>Focus on molecules: prominin-1 (CD133)</article-title><source>Exp Eye Res</source><year>2007</year><volume>85</volume><issue>5</issue><fpage>585</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2006.03.022</pub-id><pub-id pub-id-type="pmid">16733052</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Convery</surname><given-names>PA</given-names></name><name><surname>Matsumura</surname><given-names>N</given-names></name><name><surname>Whitaker</surname><given-names>RS</given-names></name><name><surname>Kondoh</surname><given-names>E</given-names></name><name><surname>Perry</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Bentley</surname><given-names>RC</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Marks</surname><given-names>JR</given-names></name><name><surname>Berchuck</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>SK</given-names></name><article-title>Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells</article-title><source>Oncogene</source><year>2009</year><volume>28</volume><issue>2</issue><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.374</pub-id><pub-id pub-id-type="pmid">18836486</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Tabu</surname><given-names>K</given-names></name><name><surname>Sasai</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Aoyanagi</surname><given-names>E</given-names></name><name><surname>Kohsaka</surname><given-names>S</given-names></name><name><surname>Tanino</surname><given-names>M</given-names></name><name><surname>Nishihara</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><article-title>Promoter hypomethylation regulates CD133 expression in human gliomas</article-title><source>Cell Res</source><year>2008</year><volume>18</volume><issue>10</issue><fpage>1037</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1038/cr.2008.270</pub-id><pub-id pub-id-type="pmid">18679414</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Ruau</surname><given-names>D</given-names></name><name><surname>Ensenat-Waser</surname><given-names>R</given-names></name><name><surname>Dinger</surname><given-names>TC</given-names></name><name><surname>Vallabhapurapu</surname><given-names>DS</given-names></name><name><surname>Rolletschek</surname><given-names>A</given-names></name><name><surname>Hacker</surname><given-names>C</given-names></name><name><surname>Hieronymus</surname><given-names>T</given-names></name><name><surname>Wobus</surname><given-names>AM</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>AM</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name><article-title>Pluripotency associated genes are reactivated by chromatin-modifying agents in neurosphere cells</article-title><source>Stem Cells</source><year>2008</year><volume>26</volume><issue>4</issue><fpage>920</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1634/stemcells.2007-0649</pub-id><pub-id pub-id-type="pmid">18203677</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Hamdbarzumyan</surname><given-names>D</given-names></name><name><surname>Becher</surname><given-names>OJ</given-names></name><name><surname>Holland</surname><given-names>EC</given-names></name><article-title>Cancer stem cells and survival pathways</article-title><source>Cell Cycle</source><year>2008</year><volume>7</volume><issue>10</issue><fpage>1371</fpage><lpage>1378</lpage><pub-id pub-id-type="pmid">18421251</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Murat</surname><given-names>A</given-names></name><name><surname>Migliavacca</surname><given-names>E</given-names></name><name><surname>Janzer</surname><given-names>RC</given-names></name><name><surname>Hegi</surname><given-names>M E</given-names></name><article-title>Stem Cell-Related "Self-Renewal" Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>18</issue><fpage>3015</fpage><lpage>3024</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.15.7164</pub-id><pub-id pub-id-type="pmid">18565887</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Hambardzumyan</surname><given-names>D</given-names></name><name><surname>Squatrito</surname><given-names>M</given-names></name><name><surname>Holland</surname><given-names>EC</given-names></name><article-title>Radiation resistance and stem-like cells in brain tumors</article-title><source>Cancer Cell</source><year>2006</year><volume>10</volume><issue>6</issue><fpage>454</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.11.008</pub-id><pub-id pub-id-type="pmid">17157785</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Clement</surname><given-names>V</given-names></name><name><surname>Sanchez</surname><given-names>P</given-names></name><name><surname>de Tribolet</surname><given-names>N</given-names></name><name><surname>Radovanovic</surname><given-names>I</given-names></name><name><surname>Ruiz i Altaba</surname><given-names>A</given-names></name><article-title>HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity</article-title><source>Curr Biol</source><year>2007</year><volume>17</volume><issue>2</issue><fpage>165</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">17196391</pub-id><pub-id pub-id-type="doi">10.1016/j.cub.2006.11.033</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Bao</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>McLendon</surname><given-names>RE</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Hjelmeland</surname><given-names>AB</given-names></name><name><surname>Dewhirst</surname><given-names>MW</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Rich</surname><given-names>JN</given-names></name><article-title>Glioma stem cells promote radioresistance by preferential activation of the DNA damage response</article-title><source>Nature</source><year>2006</year><volume>444</volume><issue>7120</issue><fpage>756</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1038/nature05236</pub-id><pub-id pub-id-type="pmid">17051156</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Griguer</surname><given-names>CE</given-names></name><name><surname>Oliva</surname><given-names>CR</given-names></name><name><surname>Gobin</surname><given-names>E</given-names></name><name><surname>Marcorelles</surname><given-names>P</given-names></name><name><surname>Benos</surname><given-names>DJ</given-names></name><name><surname>Lancaster</surname><given-names>JR</given-names><suffix>Jr</suffix></name><name><surname>Gillespie</surname><given-names>GY</given-names></name><article-title>CD133 is a marker of bioenergetic stress in human glioma</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><issue>11</issue><fpage>e3655</fpage><pub-id pub-id-type="pmid">18985161</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0003655</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Yin</surname><given-names>AH</given-names></name><name><surname>Miraglia</surname><given-names>S</given-names></name><name><surname>Zanjani</surname><given-names>ED</given-names></name><name><surname>Almeida-Porada</surname><given-names>G</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Leary</surname><given-names>AG</given-names></name><name><surname>Olweus</surname><given-names>J</given-names></name><name><surname>Kearney</surname><given-names>J</given-names></name><name><surname>Buck</surname><given-names>DW</given-names></name><article-title>AC133, a novel marker for human hematopoietic stem and progenitor cells</article-title><source>Blood</source><year>1997</year><volume>90</volume><issue>12</issue><fpage>5002</fpage><lpage>5012</lpage><pub-id pub-id-type="pmid">9389720</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Wright</surname><given-names>MH</given-names></name><name><surname>Calcagno</surname><given-names>AM</given-names></name><name><surname>Salcido</surname><given-names>CD</given-names></name><name><surname>Carlson</surname><given-names>MD</given-names></name><name><surname>Ambudkar</surname><given-names>SV</given-names></name><name><surname>Varticovski</surname><given-names>L</given-names></name><article-title>Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics</article-title><source>Breast Cancer Res</source><year>2008</year><volume>10</volume><issue>1</issue><fpage>R10</fpage><pub-id pub-id-type="pmid">18241344</pub-id><pub-id pub-id-type="doi">10.1186/bcr1855</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Eberhart</surname><given-names>CG</given-names></name><article-title>Medulloblastoma stem cells</article-title><source>J Clin Onco</source><year>2008</year><volume>26</volume><issue>17</issue><fpage>2821</fpage><lpage>2827</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.15.2264</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Monzani</surname><given-names>E</given-names></name><name><surname>Facchetti</surname><given-names>F</given-names></name><name><surname>Galmozzi</surname><given-names>E</given-names></name><name><surname>Corsini</surname><given-names>E</given-names></name><name><surname>Benetti</surname><given-names>A</given-names></name><name><surname>Cavazzin</surname><given-names>C</given-names></name><name><surname>Gritti</surname><given-names>A</given-names></name><name><surname>Piccinini</surname><given-names>A</given-names></name><name><surname>Porro</surname><given-names>D</given-names></name><name><surname>Santinami</surname><given-names>M</given-names></name><name><surname>Invernici</surname><given-names>G</given-names></name><name><surname>Parati</surname><given-names>E</given-names></name><name><surname>Alessandri</surname><given-names>G</given-names></name><name><surname>La Porta</surname><given-names>CA</given-names></name><article-title>Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential</article-title><source>Eur J Cancer</source><year>2007</year><volume>43</volume><issue>5</issue><fpage>935</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2007.01.017</pub-id><pub-id pub-id-type="pmid">17320377</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Eramo</surname><given-names>A</given-names></name><name><surname>Lotti</surname><given-names>F</given-names></name><name><surname>Sette</surname><given-names>G</given-names></name><name><surname>Pilozzi</surname><given-names>E</given-names></name><name><surname>Biffoni</surname><given-names>M</given-names></name><name><surname>Di Virgilio</surname><given-names>A</given-names></name><name><surname>Conticello</surname><given-names>C</given-names></name><name><surname>Ruco</surname><given-names>L</given-names></name><name><surname>Peschle</surname><given-names>C</given-names></name><name><surname>De Maria</surname><given-names>R</given-names></name><article-title>Identification and expansion of the tumorigenic lung cancer stem cell population</article-title><source>Cell Death Differ</source><year>2008</year><volume>15</volume><issue>3</issue><fpage>504</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4402283</pub-id><pub-id pub-id-type="pmid">18049477</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>KW</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>TK</given-names></name><name><surname>Wo</surname><given-names>JY</given-names></name><name><surname>Ng</surname><given-names>IO</given-names></name><name><surname>Zheng</surname><given-names>BJ</given-names></name><name><surname>Guan</surname><given-names>XY</given-names></name><article-title>Identification and characterization of tumorigenic liver cancer stem/progenitor cells</article-title><source>Gastroenterology</source><year>2007</year><volume>132</volume><issue>7</issue><fpage>2542</fpage><lpage>2556</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2007.04.025</pub-id><pub-id pub-id-type="pmid">17570225</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Collins</surname><given-names>AT</given-names></name><name><surname>Maitland</surname><given-names>NJ</given-names></name><article-title>Prostate cancer stem cells</article-title><source>Eur J Cancer</source><year>2006</year><volume>42</volume><issue>9</issue><fpage>1213</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2006.01.037</pub-id><pub-id pub-id-type="pmid">16632344</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Ricci-Vitiani</surname><given-names>L</given-names></name><name><surname>Lombardi</surname><given-names>DG</given-names></name><name><surname>Pilozzi</surname><given-names>E</given-names></name><name><surname>Biffoni</surname><given-names>M</given-names></name><name><surname>Todaro</surname><given-names>M</given-names></name><name><surname>Peschle</surname><given-names>C</given-names></name><name><surname>De Maria</surname><given-names>R</given-names></name><article-title>Identification and expansion of human colon-cancer-initiating cells</article-title><source>Nature</source><year>2007</year><volume>445</volume><issue>7123</issue><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1038/nature05384</pub-id><pub-id pub-id-type="pmid">17122771</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>O'Brien</surname><given-names>CA</given-names></name><name><surname>Pollett</surname><given-names>A</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name><article-title>A human colon cancer cell capable of initiating tumour growth in immunodeficient mice</article-title><source>Nature</source><year>2007</year><volume>445</volume><issue>7123</issue><fpage>106</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/nature05372</pub-id><pub-id pub-id-type="pmid">17122772</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Dalerba</surname><given-names>P</given-names></name><name><surname>Dylla</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>IK</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cho</surname><given-names>RW</given-names></name><name><surname>Hoey</surname><given-names>T</given-names></name><name><surname>Gurney</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>EH</given-names></name><name><surname>Simeone</surname><given-names>DM</given-names></name><name><surname>Shelton</surname><given-names>AA</given-names></name><name><surname>Parmiani</surname><given-names>G</given-names></name><name><surname>Castelli</surname><given-names>C</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name><article-title>Phenotypic characterization of human colorectal cancer stem cells</article-title><source>Proc Natl Acad Sci USA</source><year>2007</year><volume>104</volume><issue>24</issue><fpage>10158</fpage><lpage>10163</lpage><pub-id pub-id-type="pmid">17548814</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0703478104</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Haraguchi</surname><given-names>N</given-names></name><name><surname>Ohkuma</surname><given-names>M</given-names></name><name><surname>Sakashita</surname><given-names>H</given-names></name><name><surname>Matsuzaki</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>F</given-names></name><name><surname>Mimori</surname><given-names>K</given-names></name><name><surname>Kamohara</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><article-title>CD133+CD44+ population efficiently enriches colon cancer initiating cells</article-title><source>Ann Surg Oncol</source><year>2008</year><volume>15</volume><issue>10</issue><fpage>2927</fpage><lpage>2933</lpage><pub-id pub-id-type="doi">10.1245/s10434-008-0074-0</pub-id><pub-id pub-id-type="pmid">18663533</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>van Es</surname><given-names>JH</given-names></name><name><surname>Kuipers</surname><given-names>J</given-names></name><name><surname>Kujala</surname><given-names>P</given-names></name><name><surname>Born</surname><given-names>M van den</given-names></name><name><surname>Cozijnsen</surname><given-names>M</given-names></name><name><surname>Haegebarth</surname><given-names>A</given-names></name><name><surname>Korving</surname><given-names>J</given-names></name><name><surname>Begthel</surname><given-names>H</given-names></name><name><surname>Peters</surname><given-names>PJ</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><article-title>Identification of stem cells in small intestine and colon by marker gene Lgr5</article-title><source>Nature</source><year>2007</year><volume>449</volume><issue>7165</issue><fpage>1003</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1038/nature06196</pub-id><pub-id pub-id-type="pmid">17934449</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Boman</surname><given-names>BM</given-names></name><name><surname>Wicha</surname><given-names>MS</given-names></name><name><surname>Fields</surname><given-names>JZ</given-names></name><name><surname>Runquist</surname><given-names>OA</given-names></name><article-title>Symmetric division of cancer stem cells &#x02013; a key mechanism in tumor growth that should be targeted in future therapeutic approaches</article-title><source>Clin Pharmacol Ther</source><year>2007</year><volume>81</volume><issue>6</issue><fpage>893</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1038/sj.clpt.6100202</pub-id><pub-id pub-id-type="pmid">17460605</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Dingli</surname><given-names>D</given-names></name><name><surname>Traulsen</surname><given-names>A</given-names></name><name><surname>Michor</surname><given-names>F</given-names></name><article-title>(A)symmetric stem cell replication and cancer</article-title><source>PLoS Comput Biol</source><year>2007</year><volume>3</volume><issue>3</issue><fpage>e53</fpage><pub-id pub-id-type="pmid">17367205</pub-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.0030053</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Boman</surname><given-names>BM</given-names></name><name><surname>Fields</surname><given-names>JZ</given-names></name><name><surname>Cavanaugh</surname><given-names>KL</given-names></name><name><surname>Guetter</surname><given-names>A</given-names></name><name><surname>Runquist</surname><given-names>OA</given-names></name><article-title>How dysregulated colonic crypt dynamics cause stem cell overpopulation and initiate colon cancer</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><issue>9</issue><fpage>3304</fpage><lpage>3313</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2061</pub-id><pub-id pub-id-type="pmid">18451157</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Morrison</surname><given-names>SJ</given-names></name><name><surname>Kimble</surname><given-names>J</given-names></name><article-title>Asymmetric and symmetric stem-cell divisions in development and cancer</article-title><source>Nature</source><year>2006</year><volume>441</volume><issue>7097</issue><fpage>1068</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1038/nature04956</pub-id><pub-id pub-id-type="pmid">16810241</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Johnston</surname><given-names>MD</given-names></name><name><surname>Edwards</surname><given-names>CM</given-names></name><name><surname>Bodmer</surname><given-names>WF</given-names></name><name><surname>Maini</surname><given-names>PK</given-names></name><name><surname>Chapman</surname><given-names>SJ</given-names></name><article-title>Mathematical modeling of cell population dynamics in the colonic crypt and in colorectal cancer</article-title><source>Proc Natl Acad Sci USA</source><year>2007</year><volume>104</volume><issue>10</issue><fpage>4008</fpage><lpage>4013</lpage><pub-id pub-id-type="pmid">17360468</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0611179104</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Horst</surname><given-names>D</given-names></name><name><surname>Kriegl</surname><given-names>L</given-names></name><name><surname>Engel</surname><given-names>J</given-names></name><name><surname>Kirchner</surname><given-names>T</given-names></name><name><surname>Jung</surname><given-names>A</given-names></name><article-title>CD133 expression is an independent prognostic marker for low survival in colorectal cancer</article-title><source>Br J Cancer</source><year>2008</year><volume>99</volume><issue>8</issue><fpage>1285</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604664</pub-id><pub-id pub-id-type="pmid">18781171</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Ishii</surname><given-names>G</given-names></name><name><surname>Atsumi</surname><given-names>N</given-names></name><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>N</given-names></name><name><surname>Ochiai</surname><given-names>A</given-names></name><article-title>Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study</article-title><source>Cancer Sci</source><year>2008</year><volume>99</volume><issue>8</issue><fpage>1578</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2008.00849.x</pub-id><pub-id pub-id-type="pmid">18754869</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Shinchi</surname><given-names>H</given-names></name><name><surname>Kurahara</surname><given-names>H</given-names></name><name><surname>Mataki</surname><given-names>Y</given-names></name><name><surname>Maemura</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Natsugoe</surname><given-names>S</given-names></name><name><surname>Aikou</surname><given-names>T</given-names></name><name><surname>Takao</surname><given-names>S</given-names></name><article-title>CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer</article-title><source>Br J Cancer</source><year>2008</year><volume>98</volume><issue>8</issue><fpage>1389</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604307</pub-id><pub-id pub-id-type="pmid">18349830</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Zeppernick</surname><given-names>F</given-names></name><name><surname>Ahmadi</surname><given-names>R</given-names></name><name><surname>Campos</surname><given-names>B</given-names></name><name><surname>Dictus</surname><given-names>C</given-names></name><name><surname>Helmke</surname><given-names>BM</given-names></name><name><surname>Becker</surname><given-names>N</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Unterberg</surname><given-names>A</given-names></name><name><surname>Radlwimmer</surname><given-names>B</given-names></name><name><surname>Herold-Mende</surname><given-names>CC</given-names></name><article-title>Stem cell marker CD133 affects clinical outcome in glioma patients</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><issue>1</issue><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0932</pub-id><pub-id pub-id-type="pmid">18172261</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Beier</surname><given-names>D</given-names></name><name><surname>Wischhusen</surname><given-names>J</given-names></name><name><surname>Dietmaier</surname><given-names>W</given-names></name><name><surname>Hau</surname><given-names>P</given-names></name><name><surname>Proescholdt</surname><given-names>M</given-names></name><name><surname>Brawanski</surname><given-names>A</given-names></name><name><surname>Bogdahn</surname><given-names>U</given-names></name><name><surname>Beier</surname><given-names>CP</given-names></name><article-title>CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors</article-title><source>Brain Pathol</source><year>2008</year><volume>18</volume><issue>3</issue><fpage>370</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2008.00130.x</pub-id><pub-id pub-id-type="pmid">18371181</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tao</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Dou</surname><given-names>K</given-names></name><article-title>Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma</article-title><source>Int J Clin Pract</source><year>2008</year><volume>62</volume><issue>8</issue><fpage>1212</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1111/j.1742-1241.2008.01777.x</pub-id><pub-id pub-id-type="pmid">18479363</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>HZ</given-names></name><name><surname>Wei</surname><given-names>YP</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>YQ</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>YK</given-names></name><article-title>Association of CD133 and endothelin-converting enzyme expressions with prognosis of non-small cell lung carcinoma</article-title><source>Nan Fang Yi Ke Da Xue Xue Bao</source><year>2007</year><volume>27</volume><issue>5</issue><fpage>696</fpage><lpage>9</lpage><comment>[Article in Chinese]</comment><pub-id pub-id-type="pmid">17545092</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Jaksch</surname><given-names>M</given-names></name><name><surname>M&#x000fa;nera</surname><given-names>J</given-names></name><name><surname>Bajpai</surname><given-names>R</given-names></name><name><surname>Terskikh</surname><given-names>A</given-names></name><name><surname>Oshima</surname><given-names>RG</given-names></name><article-title>Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><issue>19</issue><fpage>7882</fpage><lpage>7886</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0723</pub-id><pub-id pub-id-type="pmid">18829544</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Rubio</surname><given-names>CA</given-names></name><article-title>Arrest of cell proliferation in budding tumor cells ahead of the invading edge of colonic carcinomas. A preliminary report</article-title><source>Anticancer Res</source><year>2008</year><volume>28</volume><issue>4C</issue><fpage>2417</fpage><lpage>2420</lpage><pub-id pub-id-type="pmid">18751428</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Gibson</surname><given-names>P</given-names></name><name><surname>Currle</surname><given-names>DS</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Richardson</surname><given-names>RJ</given-names></name><name><surname>Bayazitov</surname><given-names>IT</given-names></name><name><surname>Poppleton</surname><given-names>H</given-names></name><name><surname>Zakharenko</surname><given-names>S</given-names></name><name><surname>Ellison</surname><given-names>DW</given-names></name><name><surname>Gilbertson</surname><given-names>RJ</given-names></name><article-title>Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation</article-title><source>Nature</source><year>2009</year><volume>457</volume><issue>7229</issue><fpage>603</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1038/nature07589</pub-id><pub-id pub-id-type="pmid">19092805</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Shmelkov</surname><given-names>SV</given-names></name><name><surname>Butler</surname><given-names>JM</given-names></name><name><surname>Hooper</surname><given-names>AT</given-names></name><name><surname>Hormigo</surname><given-names>A</given-names></name><name><surname>Kushner</surname><given-names>J</given-names></name><name><surname>Milde</surname><given-names>T</given-names></name><name><surname>St Clair</surname><given-names>R</given-names></name><name><surname>Baljevic</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>I</given-names></name><name><surname>Jin</surname><given-names>DK</given-names></name><name><surname>Chadburn</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>AJ</given-names></name><name><surname>Valenzuela</surname><given-names>DM</given-names></name><name><surname>Gale</surname><given-names>NW</given-names></name><name><surname>Thurston</surname><given-names>G</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name><name><surname>D'Angelica</surname><given-names>M</given-names></name><name><surname>Kemeny</surname><given-names>N</given-names></name><name><surname>Lyden</surname><given-names>D</given-names></name><name><surname>Rafii</surname><given-names>S</given-names></name><article-title>CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors</article-title><source>J Clin Invest</source><year>2008</year><volume>118</volume><issue>6</issue><fpage>2111</fpage><lpage>2120</lpage><pub-id pub-id-type="pmid">18497886</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Lardon</surname><given-names>J</given-names></name><name><surname>Corbeil</surname><given-names>D</given-names></name><name><surname>Huttner</surname><given-names>WB</given-names></name><name><surname>Ling</surname><given-names>Z</given-names></name><name><surname>Bouwens</surname><given-names>L</given-names></name><article-title>Stem cell marker prominin-1/AC133 is expressed in duct cells of the adult human pancreas</article-title><source>Pancreas</source><year>2008</year><volume>36</volume><issue>1</issue><fpage>e1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/mpa.0b013e318149f2dc</pub-id><pub-id pub-id-type="pmid">18192867</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Florek</surname><given-names>M</given-names></name><name><surname>Haase</surname><given-names>M</given-names></name><name><surname>Marzesco</surname><given-names>AM</given-names></name><name><surname>Freund</surname><given-names>D</given-names></name><name><surname>Ehninger</surname><given-names>G</given-names></name><name><surname>Huttner</surname><given-names>WB</given-names></name><name><surname>Corbeil</surname><given-names>D</given-names></name><article-title>Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer</article-title><source>Cell Tissue Res</source><year>2005</year><volume>319</volume><issue>1</issue><fpage>15</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/s00441-004-1018-z</pub-id><pub-id pub-id-type="pmid">15558321</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Chu</surname><given-names>P</given-names></name><name><surname>Clanton</surname><given-names>DJ</given-names></name><name><surname>Snipas</surname><given-names>TS</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Mitchell</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>ML</given-names></name><name><surname>Hare</surname><given-names>E</given-names></name><name><surname>Peach</surname><given-names>RJ</given-names></name><article-title>Characterization of a subpopulation of colon cancer cells with stem cell-like properties</article-title><source>Int J Cancer</source><year>2009</year><volume>124</volume><issue>6</issue><fpage>1312</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1002/ijc.24061</pub-id><pub-id pub-id-type="pmid">19072981</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Lobo</surname><given-names>NA</given-names></name><name><surname>Shimono</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>D</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name><article-title>The biology of cancer stem cells</article-title><source>Annu Rev Cell Dev Biol</source><year>2007</year><volume>23</volume><fpage>675</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.22.010305.104154</pub-id><pub-id pub-id-type="pmid">17645413</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Merlo</surname><given-names>LM</given-names></name><name><surname>Pepper</surname><given-names>JW</given-names></name><name><surname>Reid</surname><given-names>BJ</given-names></name><name><surname>Maley</surname><given-names>CC</given-names></name><article-title>Cancer as an evolutionary and ecological process</article-title><source>Nat Rev Cancer</source><year>2006</year><volume>6</volume><issue>12</issue><fpage>924</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1038/nrc2013</pub-id><pub-id pub-id-type="pmid">17109012</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Yilmaz</surname><given-names>OH</given-names></name><name><surname>Valdez</surname><given-names>R</given-names></name><name><surname>Theisen</surname><given-names>BK</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Ferguson</surname><given-names>DO</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name><article-title>Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells</article-title><source>Nature</source><year>2006</year><volume>441</volume><issue>7092</issue><fpage>475</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1038/nature04703</pub-id><pub-id pub-id-type="pmid">16598206</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Yilmaz</surname><given-names>OH</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name><article-title>The PI-3kinase pathway in hematopoietic stem cells and leukemia-initiating cells: a mechanistic difference between normal and cancer stem cells</article-title><source>Blood Cells Mol Dis</source><year>2008</year><volume>41</volume><issue>1</issue><fpage>73</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">18387833</pub-id><pub-id pub-id-type="doi">10.1016/j.bcmd.2008.02.004</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Willis</surname><given-names>ND</given-names></name><name><surname>Przyborski</surname><given-names>SA</given-names></name><name><surname>Hutchison</surname><given-names>CJ</given-names></name><name><surname>Wilson</surname><given-names>RG</given-names></name><article-title>Colonic and colorectal cancer stem cells: progress in the search for putative biomarkers</article-title><source>J Anat</source><year>2008</year><volume>213</volume><issue>1</issue><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1111/j.1469-7580.2008.00917.x</pub-id><pub-id pub-id-type="pmid">18638071</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Shibata</surname><given-names>D</given-names></name><article-title>Stem cells as common ancestors in a colorectal cancer ancestral tree</article-title><source>Curr Opin Gastroenterol</source><year>2008</year><volume>24</volume><issue>1</issue><fpage>59</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1097/MOG.0b013e3282f2a2e9</pub-id><pub-id pub-id-type="pmid">18043234</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Zou</surname><given-names>GM</given-names></name><article-title>Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver</article-title><source>J Cell Physiol</source><year>2008</year><volume>217</volume><issue>3</issue><fpage>5q98</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1002/jcp.21541</pub-id></mixed-citation></ref></ref-list></back></article>